Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands

TPR seems a cost-effective alternative to PR in TN patients and dominant in TE patients. TPR was a dominant, more effective and less costly alternative to BPR in both patient types. The cost effectiveness of both TPR and BPR is well below generally accepted willingness-to-pay thresholds and may be considered cost effective. </AbstractSection> Copyright Springer International Publishing Switzerland 2014

MoreLess

Year of publication:	2014
Authors:	Vellopoulou, Aikaterini ; Agthoven, Michel ; Kolk, Annemarie ; Knegt, Robert ; Berdeaux, Gilles ; Cure, Sandrine ; Bianic, Florence ; Lamotte, Mark
Published in:	Applied Health Economics and Health Policy. - Springer, ISSN 1175-5652. - Vol. 12.2014, 6, p. 647-659
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011152168